EQL Pharma signs a license agreement with a large pharmaceutical company in Türkiye for Mellozzan (melatonin)
EQL has entered into an exclusive license agreement with a large pharmaceutical company for its product Mellozzan (melatonin) for Türkiye and Kazakhstan. "EQL has previously signed license agreements with parties for a number of countries, but this is a milestone as it is our first agreement with the sale of one of our products outside the borders of Europe," says Axel Schörling, CEO at EQL Pharma.Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan